Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2. These studies show the potential of DATROWAY (datopotamab deruxtecan), which is a TROP2-directed DXd ADC that improves outcomes for patients with non-small cell lung cancer/NSCLC across various disease stages when used in combination with different immunotherapies.

Is Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLCPLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?

A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.

These results were announced at the 2025 ASCO Annual Meeting. DATROWAY was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca. Final Phase 1b TROPION-Lung02 data showed that DATROWAY plus pembrolizumab as a first-line advanced NSCLC treatment achieved a 54.8% ORR in 42 patients (doublet) and 55.6% ORR in 54 patients when platinum chemotherapy was added (triplet). Safety profiles were also consistent.

Additionally, Phase 1b TROPION-Lung04 results, presented earlier on May 31, showed that DATROWAY combined with AstraZeneca’s rilvegostomig achieved a 57.5% ORR and 95% disease control rate in 40 advanced/metastatic NSCLC patients. This combination is now in Phase 3. Finally, Phase 2 NeoCOAST-2 trial data, also presented on May 31, showed that neoadjuvant DATROWAY with AstraZeneca’s IMFINZI and platinum chemotherapy resulted in a 35.2% pathologic complete response rate and 63% major pathologic response rate in early-stage resectable NSCLC.

DATROWAY is already approved in over 30 countries for HR-positive, HER2-negative breast cancer. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines. Whereas Daiichi Sankyo Company Limited (OTC:DSNKY) manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally.

While we acknowledge the potential of DSNKY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DSNKY and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.